Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 7.
Figure 7.

Network-based discovery of repurposable drug candidates for AD by specifically reversing gene expression of DAM and DAA. (A) Selected drugs that specifically target five different DAM or DAA molecular networks. Drug are grouped by five different classes (immunological, respiratory, neurological, cardiovascular, and cancer) (Supplemental Table S12) defined by the first-level of the Anatomical Therapeutic Chemical (ATC) codes. Four high-confidence drugs (fluticasone, mometasone, salbutamol, and tretinoin) were highlighted. (B,C) Proposed mechanism-of-actions for two selected drugs (tretinoin [B] and salbutamol [C]) by drug-target network analysis.

This Article

  1. Published in Advance February 24, 2021, doi: 10.1101/gr.272484.120 Genome Res. 31: 1900-1912

Preprint Server



Current Issue

  1. March 2026, 36 (3)
  1. Current Issue
  1. Alert me to new issues of Genome Research